This is a preview of subscription content, log in via an institution to check access.
Notes
2013 British pounds
Reference
Hinde S, et al. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. Value in Health 19: 431-9, No. 4, Jun 2016. Available from: URL: http://doi.org/10.1016/j.jval.2016.01.013
Rights and permissions
About this article
Cite this article
Bevacizumab not cost effective for advanced ovarian cancer. PharmacoEcon Outcomes News 756, 12 (2016). https://doi.org/10.1007/s40274-016-3161-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3161-7